Investment analysts at Goldman Sachs Group, Inc. (The) initiated coverage on shares of Thermo Fisher Scientific Inc (NYSE:TMO) in a research note issued to investors on Tuesday. The firm set a “buy” rating and a $225.00 price target on the medical research company’s stock. Goldman Sachs Group, Inc. (The)’s price objective indicates a potential upside of 20.11% from the company’s current price.

TMO has been the topic of several other research reports. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price objective on the stock in a research note on Thursday, September 7th. Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. Morgan Stanley restated an “overweight” rating and issued a $220.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, September 6th. Finally, BidaskClub downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 27th. One research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Thermo Fisher Scientific has an average rating of “Buy” and a consensus target price of $199.13.

Shares of Thermo Fisher Scientific (NYSE TMO) traded up 0.34% on Tuesday, hitting $188.31. 770,997 shares of the stock traded hands. The stock has a market cap of $73.46 billion, a price-to-earnings ratio of 32.81 and a beta of 1.05. The stock has a 50-day moving average price of $181.07 and a 200 day moving average price of $171.15. Thermo Fisher Scientific has a 12-month low of $139.07 and a 12-month high of $194.30.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating the consensus estimate of $2.27 by $0.03. The company had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.03 earnings per share. On average, analysts anticipate that Thermo Fisher Scientific will post $9.34 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/goldman-sachs-group-inc-the-reiterates-conviction-buy-rating-for-thermo-fisher-scientific-inc-tmo/1589603.html.

In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 11,318 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 18th. The stock was sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the completion of the transaction, the director now directly owns 38,757 shares of the company’s stock, valued at $6,702,635.58. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jim P. Manzi sold 1,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $175.20, for a total value of $175,200.00. Following the transaction, the director now directly owns 38,757 shares of the company’s stock, valued at $6,790,226.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,738 shares of company stock valued at $9,302,112. 0.49% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of TMO. Proficio Capital Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 71.5% during the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after acquiring an additional 253 shares during the period. Chicago Partners Investment Group LLC bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at $108,000. Cribstone Capital Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 8.7% during the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after acquiring an additional 50 shares during the period. Sharkey Howes & Javer lifted its holdings in shares of Thermo Fisher Scientific by 1.0% during the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 7 shares during the period. Finally, Shine Investment Advisory Services Inc. bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at $113,000. 83.36% of the stock is owned by institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.